Curative Biotechnology (OTCMKTS:CUBT – Get Rating) and Baudax Bio (NASDAQ:BXRX – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Institutional and Insider Ownership

21.1% of Baudax Bio shares are held by institutional investors. 0.5% of Baudax Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Get Curative Biotechnology alerts:

Earnings & Valuation

This table compares Curative Biotechnology and Baudax Bio's revenue, earnings per share and valuation.

Curative Biotechnology has higher earnings, but lower revenue than Baudax Bio.

Analyst Ratings

This is a summary of recent recommendations and price targets for Curative Biotechnology and Baudax Bio, as provided by MarketBeat.

Baudax Bio has a consensus price target of $1.00, indicating a potential upside of 421.10%. Given Baudax Bio's higher possible upside, analysts clearly believe Baudax Bio is more favorable than Curative Biotechnology.

Profitability

This table compares Curative Biotechnology and Baudax Bio's net margins, return on equity and return on assets.

Volatility & Risk

Curative Biotechnology has a beta of -19.29, indicating that its stock price is 2,029% less volatile than the S&P 500. Comparatively, Baudax Bio has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500.

Summary

Baudax Bio beats Curative Biotechnology on 6 of the 9 factors compared between the two stocks.

About Curative Biotechnology

(Get Rating)

Curative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.

About Baudax Bio

(Get Rating)

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

Receive News & Ratings for Curative Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curative Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.